Pharming Group N.V. (PHAR) Tops Q3 EPS by 12c

Pharming Group N.V. (NASDAQ: PHAR) reported Q3 EPS of $0.01, $0.12 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $66.7 million versus the consensus estimate of $61.66 million.

For earnings history and earnings-related data on Pharming Group N.V. (PHAR) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c